Aim To provide evidence regarding the effectiveness of aripiprazole in improving penile erection with a therapeutic strategy of add-on or switching therapy in patients with schizophrenia. Methods PubMed, Cochrane, Clinical Key, ProQuest, EBSCOhost, and ScienceDirect were searched for any design study that evaluated aripiprazole only or versus control (placebo or other antipsychotic) for erectile dysfunction in patients with schizophrenia. Three studies were identified and analysed from 295 initial articles. Data were then extracted from the studies and summarized descriptively. Results Two hundred ninety-five articles were screened, and three studies were identified and eventually selected. After the add-on or switching antipsychotic therapy to aripiprazole, the prevalence of erectile dysfunction and the score of erectile dysfunction or penile erection assessed by Nagoya and Sexual Function Questionnaire (NSFQ) and Arizona Sexual Experience Scale (ASEX) decreased. Conclusion Aripiprazole was effective to improve penile erectile function in patients with schizophrenia. The therapeutic strategy is adjunctive treatment or switching therapy to aripiprazole.
Owen M, Sawa A, Mortensen P, Schizophrenia. Lancet. 2016. p. 86–97.
2.
Fatani B, Aldawod R, Alhawaj F. Schizophrenia: etiology, pathophysiology, and management : a review. Egypt J Hosp Med. 2017. p. 2640–6.
3.
Meyer N, Maccabe J. Schizophrenia. Med (United Kingdom). 2016. p. 649–53.
4.
Indonesian Ministry of Health. Hasil utama riset kesehatan dasar (RISKESDAS) (Main result of basic health data) [In Indonesian]. 2018.
5.
Miyamoto B, Galecki M, Francois D. Guidelines for antipsychotic-induced hyperprolactinemia. Psychiatr Ann. 2015. p. 266–72.
6.
Yeon W, Yooseok K, Jun H. Antipsychotic induced sexual dysfunction and its management. World J Mens Health. 2012. p. 153–9.
7.
Anthony J, Rany S. Psychotropics and sexual dysfunction. Cent European J Urol. 2013. p. 466–71.
8.
Chisholm-Burns M, Wells B, Schwinghammer T, Malone P, Kolesar J, Dipiro J. Pharmacotherapy: Principles & Practice. McGraw-Hill Education; 2016.
9.
Hanssens L, ’italien L, Loze G, Marcus J, Pans R, Kerselaers M, et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry. 2008. p. 1–11.
10.
Mahmoud A, Hayhurst K, Drake R, Lewis S. Second generation antipsychotics improve sexual dysfunction in schizophrenia: a randomized controlled trial. Schizophr Res Treatment. 2011.
11.
Tuplin E, Holahan M. Aripiprazole, a drug that displays partial agonism and functional selectivity. Curr Neuropharmacol. 2017. p. 1192–207.
12.
Mir A, Shivakumar K, Williamson R, Mcallister V, ’keane O, Aitchison V, et al. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol. 2008. p. 244–53.
13.
Hanssens L, ’italien L, Loze G, Marcus J, Pans R, Kerselaers M, et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry. 2008. p. 95.
14.
Khan A, Nawaz H, Nazneen Z, Yousafzai A. Antipsychotics induced sexual dysfunction. Pakistan J Physiol. 2017. p. 3–7.
15.
Liberati A, Altman D, Tetzlaff J, Mulrow C, Gøtzsche P, Ioannidis J. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009. p. 56–62.
16.
Byron C Wallace J, Kuiper A, Sharma M, Zhu I. Extracting PICO Sentences from Clinical Trial Reports using Supervised Distant Supervision. J Mach Learn Res. 2016. p. 90–8.
17.
Fujioi J, Iwamoto K, Banno M, Kikuchi T, Aleksic B, Ozaki N. Effect of adjunctive aripiprazole on sexual dysfunction in schizophrenia: a preliminary open-label study. Pharmacopsychiatry. 2017. p. 74–8.
18.
Jeong H, Lee M, Lee H, Ko Y, Han C, Joe S. Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study. Int Clin Psychopharmacol. 2012. p. 177–83.
19.
Raghuthaman G, Venkateswaran R, Krishnadas R. Adjunctive aripiprazole in risperidone-induced hyperprolactinemia: a double-blind, randomized, placebo-controlled trial. Br J Psych Open. 2015. p. 172–7.
20.
Kikuchi T, Iwamoto K, Sasada K, Aleksis B, Yoshida K, Ozaki N. Reliability and validity of a new sexual function questionnaire (Nagoya Sexual Function Questionnaire) for schizophrenic patients taking antipsychotics. Hum Psychopharmacol. 2011. p. 300–6.
21.
Mcgahuey C, Gelenberg A, Laukes C, Moreno F, Delgado P, Mcknight K. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000. p. 25–38.
22.
Tsertsvadze A, Fink H, Yazdi F, Macdonald R, Bella A. Clinical guidelines annals of internal medicine oral phosphodiesterase-5 inhibitors and hormonal treatments. Ann Intern Med. 2009. p. 650–61.
23.
Kevan, Ian. Handbook of Sexual Dysfunction. Taylor & Francis Ltd; 2005. p. 155–91.
24.
Peter F, Timothy G. Prolactin and dopamine: what is the connection? a review article. J Psychopharmacol. 2008. p. 12–9.
25.
Saleem M, Martin H, Coates P. Prolactin biology and laboratory measurement: an update on physiology and current analytical issues. Clin Biochem Rev. 2018. p. 3–16.
26.
Banerjee A, Chitnis U, Jadhav S, Bhawalkar J, Chaudhury S. Hypothesis testing, type I and type II errors. Ind Psychiatry J. 2009. p. 127–31.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
